The major amyloid beta (Aβ) peptides found in the brain of familial and late onset Alzheimer's disease include the full-length Aβ1-42 and N-terminally truncated, pyroglutamylated peptides Aβp3-42 and Aβp11-42. The biophysical properties of Aβ1-42 have been extensively studied, yet little is known about the other modified peptides. We investigated the aggregation kinetics of brainspecific Aβ peptides to better understand their potential roles in plaque formation. Synthetic peptides were analyzed individually and in mixtures representing various ratios found in the brain. Spectrofluorometric analyses using Thioflavin-T showed that the aggregation of Aβ1-42 was faster compared to Aβp3-42; however, Aβp11-42 displayed similar kinetics. Surprisingly, mixtures of fulllength Aβ1-42 and Aβp3-42 showed an initial delay in beta-sheet formation from both equimolar and non-equimolar samples. Electron microscopy of peptides individually and in mixtures further supported fluorescence data. These results indicate that Aβ-Aβ peptide interactions involving different forms may play a critical role in senile plaque formation and maintenance of the soluble Aβ pool in the brain.
Introduction
Protein aggregation is a pathological feature of many neurodegenerative diseases. Alzheimer's disease (AD), the most prevalent form of senile dementia, is characterized by extracellular deposits of amyloid-beta (Aβ) peptides forming the characteristic senile plaques [7] . Aβ is a 39 to 43 amino acid peptide derived through the proteolytic processing of the amyloid precursor protein (APP) [32] . Cleavage of this transmembrane protein by specific secretases, releases a family of Aβ peptides, which subsequently aggregate to form larger fibrillar structures ultimately developing into diffuse or compact senile plaques [32] . This process appears to be accelerated in both familial AD and Down's syndrome (DS). Familial AD is caused by mutations in genes encoding either APP or presenilins 1 or 2, which participate in APP proteolytic processing among other genes [1, [3] [4] [5] [6] 8, 13, 14, 26, 33] . Individuals with these mutations develop symptoms much earlier in life compared to late onset AD. In DS, increased expression of the APP gene as a result of trisomy 21, also leads to Alzheimer-like pathology early in life [21, 32] .
Senile plaques are composed primarily of a mixture of both 40 and 42 amino acid Aβ peptides. Full-length Aβ1-42 predominates in both AD and DS [7, 18, 22, 36] . Numerous studies have shown that Aβ1-42 has a greater propensity to aggregate compared to the shorter counterpart, Aβ1-40 [2] . Analysis of the senile plaques as well as water-soluble Aβ has revealed a heterogeneous mixture of truncated, modified peptides along with full-length Aβ peptides [12, 16, 18, 24, 26, 28, 29, 34] . Two N-terminally truncated peptides, Aβp3-42 and Aβp11-42, have their N-terminal glutamates cyclized. The two peptides are interesting in that both are found in plaques of AD and DS brains, and specifically in DS brain, are present in soluble form long before the appearance of insoluble plaques [24, 25, 36] . Despite difficulties in measuring these peptides in brain extracts, microgram levels of the modified peptides were found in both AD and DS brain [36] . For instance, the concentration of Aβp3-42 has been shown to increase as the disease progresses and in some cases may account up to 25% of the total Aβ load [10, 24] . Moreover, Aβp11-42 is specifically elevated in certain familial cases with presenilin mutations [26] . Due to structural modifications, both pyroglutamylated peptides are more resistant to peptidases, which may explain their dominance in senile plaques [28] . Furthermore, N-terminal truncation of Aβ peptides increases their hydrophobicity, which leads to increased propensity to aggregate compared to Aβ1-42 [19] . However, to date no exhaustive comparative analyses of the N-terminally truncated, pyroglutamylated peptides have been conducted.
In this study, we set out to compare the aggregation kinetics of synthetic full-length Aβ1-42, Aβp3-42, and Aβp11-42 peptides. We used Thioflavin-T (ThT) as an indicator of β-sheet formation to monitor peptide aggregation. Our results show that full-length Aβ1-42 forms β-sheets more readily compared to the N-terminally modified peptides. Yet unexpectedly, Aβp3-42 added to full-length Aβ1-42 at various ratios causes significant alterations in the propensity of full-length Aβ1-42 to aggregate specifically during the initial phases of aggregation.
Materials and methods

Chemicals and peptides
Synthetic Aβ peptides were purchased from AnaSpec (San Jose, CA): Aβ1-42 (Lot n.31475), Aβp3-42 (Lot n.29907), Aβp11-42 (Lot n.29903). HEPES free acid, Glycerol, and 2-mercaptoethanol were purchased from Sigma Aldrich (St.Louis, MO). TRIS, Acrylamide (Electrophoretic grade), Bis-acrylamide (Electrophoretic grade), Glycine, Tricine, Methanol (HPLC grade), Sodium Chloride, and Coomassie Brilliant Blue G-250 were purchased from Fisher Chemicals (Atlanta, GA). Sodium dodecyl sulphate (SDS) was purchased from BioRad (Hercules, CA). 1,1,1,3,3,3-Hexafluoro-2-propanol (HFIP) and Thioflavin-T (ThT) were purchased from Sigma Aldrich (St.Louis, MO). Sodium phosphotungstate was purchased from Sigma (St.Louis, MO) and Formvar substrate-Nickel grids for Electron Microscopy were purchased from Ladd Research (Williston, VT).
Aβ sample preparation
One mL of cold 1,1,1,3,3,3-hexafluoro-2-propanol (HFIP) was added to 1mg of lyophilized peptide, for a final concentration of 1mg/mL. Aliquots of 100µL were stored in −80°C until needed. Before experiments, the required amounts of peptides in HFIP were aliquoted and vacufuged for 10 minutes. A mixture of 0.2% NHOH 4 and 100mM Hepes at a ratio of 1:9 was added to solubilize dried peptides for approximately 5-10 minutes followed with 500mM Hepes and double-deionized H 2 O. All solutions were prepared at physiological pH of 7.4. Aβ samples were constantly stirred throughout the experiments at 25°C.
Fluorometic analysis
Thioflavin-T was added to each Aβ sample to a final concentration of 20µM. Peptide aggregation was monitored by recording ThT fluorescence using the SPEX Fluoromax-3 spectrofluorometer (HORIBA Group, Edison, NJ). ThT excitation and emission wavelengths were 450nm and 485nm, respectively. Measurements were taken every 15 minutes for the first two hours and every hour thereafter up to 24 hours. Every effort was made to minimize exposure of samples to light to avoid degradation of ThT. All experiments were independently conducted a minimum of three times. Vehicle samples without peptide were prepared fresh for each assay conducted. Fluorescence readings from Aβ samples were corrected for background changes in fluorescence by subtracting values from vehicle preparations without peptide. Results are expressed as average fluorescence units with mean values ± SE of a minimum of three independent experiments. ANOVA followed by Fisher's Post-Hoc analysis was conducted on each sample for each individual time point. Statistical significance was achieved with p values less than 0.05.
Western Blot
Samples were analyzed for the presence of specific peptides and aggregates by Western blotting. Sample buffer without reducing agents such as SDS or β-mercaptoethanol was added to all samples. Non-denaturing tris-tricine gels were cast to separate monomeric from aggregate structures. Membranes were probed with antibody 4G8 (SENETEK, Napa, CA) specific for residues 17-24 of Aβ and antibody PC421 specific for Aβx-42. Membranes were also probed with antibodies AβN3(pE) and AβN11(pE) provided by T.C. Saido to identify pyroglutamylated species Aβp3-42 and Aβp11-42, respectively [28] .
Electron microscopy
Peptide samples were prepared as described for the ThT experiments and aggregated at 25°C with constant agitation. Five to ten µL of sample preparation was added to carbon and Formvarcoated nickel grids for 3-5 minutes and blotted with filter paper. A 2% solution of sodium phosphotungstate at pH 7.0 was added immediately as the staining agent. After one minute the grid was quickly and completely dried with filter paper. Grids were analyzed using the FEI/ Philips EM 208S transmission electron microscope. Two grids were treated for each sample analyzed. Multiple images were taken from each grid and images shown are representative peptide structures observed on the grids at the indicated times. Grids of the vehicle only were analyzed to discriminate between actual peptide and background.
Results
We prepared samples using synthetic Aβ peptides and analyzed the rate of aggregation by monitoring ThT fluorescence to compare the kinetics of aggregation of full-length Aβ1-42 and the N-terminally truncated, pyroglutamylated peptides Aβp3-42 and Aβp11-42. Individual peptide samples were prepared at final concentrations of 5µM. Small volumes were collected for the analysis of peptide aggregates by using Western blotting. As expected, membranes probed with the antibody 4G8 confirmed the presence and predominance of monomeric forms in each sample at the beginning of the assays (Fig.1A, B) .
Inspection of the fluorometric data indicates that full-length Aβ1-42 aggregates similarly to Aβp11-42, yet much faster than Aβp3-42 (Fig.2) . In repeated assays, 5µM Aβ1-42 and Aβp11-42 reached maximum ThT fluorescence between three to five hours, while contrary to previous findings, aggregation of 5µM Aβp3-42 was much slower [12, 27] . In fact, the time required to reach 50% of the maximum fluorescence intensity, the T 50 value, for Aβ1-42 was just under three hours while Aβp3-42 reached half maximum many hours later (data not shown). However, Western blot analysis confirmed the presence of larger aggregates formed from all peptides at the end of the assays showing antibody labeling at the bottom of loading wells, suggesting the presence of larger aggregates (Fig.1C-E) .
From individual fluorescence data, we hypothesized that preparing mixtures of the fastest and slowest aggregating peptides would result in intermediate kinetics. Since Aβ1-42 and Aβp3-42 aggregated the fastest and slowest respectively, we prepared various mixtures of the two peptides and measured ThT fluorescence over time. In our first mixture at 10µM, we observed lower fluorescence readings early (Fig.2 ), yet higher readings as aggregation continued which was expected due to the higher concentration of peptides [15] . However, fluorescence measurements did not reach that of Aβ1-42 alone until after it reached maximum fluorescence. Next, we prepared mixtures of the two peptides at a concentration of 2.5 µM each. Surprisingly, this peptide mixture aggregated in the same fashion as reported for 5µM Aβp3-42 alone (Fig.  2) . Therefore, the data suggests that in equimolar mixtures at two different concentrations, Aβp3-42 delayed early aggregation of Aβ1-42. Again, Western blots confirmed the presence of both peptides at the beginning of the assay in monomeric form (Fig.1B) . Samples collected at the end of the assay confirm the presence of peptide aggregates at the bottom of loading wells (Fig.1D, E) , indicating the formation of larger homogeneous or heterogeneous aggregates similar to those seen in brain extracts [28] .
To test whether the same effect could be reproduced at other peptide ratios, we prepared nonequimolar mixtures with final concentrations of 6µM. A five to one micromolar ratio of fulllength to Aβp3-42 aggregated similarly to 6µM Aβ1-42 alone (Fig.3) . However, a two to one ratio displayed the same delay in aggregation as observed earlier in equimolar mixtures. A final equimolar mixture of 3µM Aβ1-42 and 3µM Aβp3-42 reproduced that of Aβp3-42 aggregation at 6µM alone (Fig.3 ). It appears that as more Aβp3-42 was added with Aβ1-42, a reduction in ThT incorporation occurred early, indicative of a delay in beta-sheet formation during initial stages of aggregation. In addition, T 50 values for the peptide mixture at a ratio of 2:1 were approximately 4.8 hours, which was significantly higher than the T 50 of full-length Aβ1-42 alone, which was less than two hours (data not shown). Therefore, these results further supports the notion that the N-terminally truncated, modified peptide Aβp3-42 exerts an inhibitory affect on aggregation of full-length Aβ1-42, specifically during early phases.
According to our data, the greatest difference in aggregation occurred two to four hours into the fluorometric assay. This difference was observed for the full-length Aβ1-42 and Aβp3-42 peptides individually as well as in mixtures of the two peptides. To observe the peptide aggregates, we analysed samples collected after two and four hours using electron microscopy (EM) and found heterogeneous structures present in most samples. Images of 6µM Aβ1-42 displayed mostly immature fibrillar structures similar to those described previously (Fig.4A,  B) [31] . The criteria included the occurrence of flexions and curved fibers. We did observe shorter, curly fibers from the two hour time point; yet the majority were longer, fibrillar structures with multistrand organization [31] . Images of 6µM Aβp3-42 showed mostly short fibers aligned side-by-side forming small bundles (Fig.4C, D) . Bundles of short, aligned fibers and mostly curly fibers loosely gathered were also present (Fig.4D) . Although EM is not quantitative, images of Aβp3-42 forming immature fibers were difficult to locate when compared to full-length Aβ1-42, which was consistent with our fluorescence data.
EM images from mixtures of 3µM Aβ1-42 and 3µM Aβp3-42 were fairly similar to Aβp3-42 images captured at both time points (Fig.4 E, F) ; mostly patches of smaller bundles consisting of short, straight and curly fibers. Images taken after two hours of the 4µM Aβ1-42 and 2µM
Aβp3-42 mixture showed a few patches of longer fibers forming a net-like structure surrounded by globular chains as previously reported (Fig.4 G) [27, 38] . After four hours of aggregation, there appeared an abundance of immature fibrillar structures similar to Aβ1-42 with structures previously observed including the flexions, curved fibers, and multistrand twistings (Fig.4H ).
Discussion
Alzheimer's disease develops over many years before any symptoms appear. The exact pathogenic mechanisms of this illness have not been elucidated. However, since the discovery and isolation of Aβ peptides as the major component of senile plaques found in AD brain, the focus has been centered on these peptides [7] . In particular, the accumulation of the heterogeneous peptide isoforms may be considered causative in the development of the disease [1, [3] [4] [5] [6] [7] [8] [9] 13, 14, 20, 25, 26, 33] . Due to its prevalence in senile plaques and unusual propensity to aggregate, full length Aβ1-42 has been extensively studied [7, 22, 23] . Less attention has been devoted to the truncated, modified peptides also abundant in the brain.
Since truncated, pyroglutamylated Aβ peptides aggregate more readily, are more resistant to proteases, and are prevalent in AD and DS brain, we specifically included these peptides in our studies [16, 19, 24, 28, 29] . The aggregation of non-modified peptides may precede the formation of cyclized glutamate residues, however the observation from Teller et al. that modified peptides are found in abundance in diffuse plaques strongly suggests that the modification indeed occurs prior to plaque formation [25, 30, 36] . Our goals were to study the aggregation of synthetic, brain-specific, N-terminally truncated, modified peptides and compare to that of full-length Aβ1-42. As the levels of the pyroglutamylated peptides are elevated in the brain of AD and DS individuals and that senile plaque are heterogeneous in nature, we also decided to visually analyze mixtures representing peptide ratios found in the brain.
We report here that full-length Aβ1-42 aggregates faster than the specific N-terminally truncated, pyroglutamylated Aβp3-42 isoform; yet the rate of aggregation of Aβp11-42 is quite similar, if not the same. This is not consistent with previous reports indicating that N-terminally truncated, pyroglutamylated peptides aggregate faster than full-length Aβ peptides [12, 19, 27] . It is important to note that in Pike et al.'s study, the modified peptides were not analyzed [19] . The cyclization of glutamate residues, which alters the peptide structure, may affect the aggregation propensity. He et al. and Russo et al. reported enhanced aggregation of the pyroglutamylated peptides compared to the full-length peptide [12, 27] . Their studies differ significantly from our study since they used shorter, 28 and 40 amino acid long Aβ peptides, used much higher concentrations of peptides, and analyzed peptides only after three days of incubation at 37° C. Other studies using full-length Aβ1-42 and Aβp3-42 have reported betapleated sheets present in both fresh and aged peptides, however beta-sheet formation through time was not analyzed [35] . Furthermore, our study shows a delay in the early phases of aggregation, not fibrillization. The fluorescence data of Aβp3-42 as well as EM images shows that at the early time points, the peptide gradually makes the transition from smaller aggregates into fibrillar structures, leading us to speculate that the seeding or nucleation phase may be slower. However, fluorescence measurements of Aβp3-42 aggregation after ten hours did show a continuous rise in ThT fluorescence (data not shown), indicating both aggregation and fibrillization had occurred. Western blot analyses of Aβp3-42 show larger structures at the end of aggregation assays from samples analyzed many hours later, further suggesting that both aggregation and fibrillization had occurred.
Reasons for this discrepancy may be that binding of ThT is altered while in the presence of Aβp3-42 due to both N-terminal truncation and peptide structure. In contrast, fluorometric analysis showed that ThT bound well to the Aβp11-42 isoform, dismissing this idea. Yet the difference between the isoforms is the overall length of the peptides and their hydrophobicity. Greater hydrophobicity of Aβp11-42 due to an increased number of charges removed would explain its higher propensity to aggregate, despite modification. The Aβp3-42, in contrast, is perhaps unable to form stable structures compared to other peptides. It is possible that larger structures were being formed but were unstable and as a result the formation of fibrils, where ThT could intercalate was impaired. Nevertheless, there were plenty of variables that could have accounted for the differences in published data such as solutions used, pH values, total concentrations, temperature, etc. These aspects could have caused differences by either accelerating or impeding the aggregating process.
At three separate equimolar mixtures of full-length Aβ1-42 and Aβp3-42, we found that aggregation was altered during the initial hours. Both 2.5µM and 5.0µM per peptide mixtures showed a delay in early aggregation when compared to Aβ1-42 alone, while 3µM per peptide mixtures altered aggregation throughout the entire time course. One could speculate the lower fluorescence readings indicative of delays in aggregation, could have been the result of lower Aβp3-42 concentrations in the mixed samples. However, this is not seen in those mixtures with 2.5µM and specifically 5.0µM per peptide. With equimolar ratios, it is clearly observed that the delay in aggregation remains within the initial hours of aggregation assays. Yet, we were compelled to conduct nonequimolar aggregation assays to not only, mimic those ratios found in the diseased brain but to also compare individual peptide assays to that of mixed samples with the same total concentration. In this way, proper analyses on the aggregation of mixed samples could be made. Thus, it appears that Aβp3-42 had an affect on the initial process of aggregate formation while in the presence of Aβ1-42, which was not surprising given the aggregation of Aβp3-42 alone. From the EM images, it was clear that the presence of longer extending fibers and fiber bundles, characteristic of Aβ1-42, was increased as the Aβp3-42 amount decreased. As more Aβp3-42 was added to full-length Aβ1-42 however, the appearance of compact fibrillar structures became much more difficult to discern compared to ratios favoring Aβ1-42. This latter observation further supported the fluorescence data in suggesting an inhibitory role of Aβp3-42 on Aβ1-42 aggregation.
The inhibitory role of Aβp3-42 in the aggregation of full-length Aβ1-42 has not been reported. A possible mechanism may involve a disruption in nucleation or the seeding process by Aβp3-42, which inhibits the early phase of Aβ1-42 aggregation. This disruption may be the result of the structural modification present in Aβp3-42, which may obstruct peptide interaction. Another mechanism may involve Aβp3-42 forming unstable aggregates, which may collapse and potentially affect other larger aggregates. The deposition of Aβp3-42 early in the brain may constitute a mechanism to prevent or disrupt the deleterious accumulation of Aβ peptides. This may appear to contradict the recent studies by Schilling et al. (2006) , in which the authors demonstrated that N-terminal truncation and in particular, pyroglutamyl formation may lead to increased amyloidogenicity [30] . In our fluorescence data, one could also speculate that Aβp3-42 may increase aggregation upon interaction with Aβ1-42. Unfortunately, we did not focus on the fibrillization phases but instead focused our efforts on the initial phases of aggregation. However, it is of note that as reported by both Zou et al. and Yan et al., the Aβ1-40 had similar inhibitory effects on the aggregation of full-length Aβ1-42 as the modified peptide Aβp3-42 had on Aβ1-42 in our study: in the presence of Aβ1-40, transition of Aβ1-42 to beta-sheet was reduced as shown by circular dichroism spectroscopy, electron microscopy and nuclear magnetic resonance [37, 39] . Yan et al. conducted an elegant experiment showing monomeric Aβ1-42 species decreasing after only 3hours of aggregation on Western blots [37] . When Aβ1-40 monomers were introduced with Aβ1-42, monomeric forms of Aβ1-42 remained much longer indicative of an inhibition of Aβ1-42 aggregation by Aβ1-40. Hasegawa et al. kept constant Aβ1-42 concentrations while changing Aβ1-40 and as well as kept Aβ1-40 constant while Aβ1-42 levels changed [11] . Although their focus was on the interaction of different species of peptides, they reported a similar inhibitory effect characterized by an interruption in Aβ1-42 conformation changes during the nucleation or initial phases of aggregation. We believe our studies would mimic those of Hasegawa and Yan et al. when conducted in a similar fashion [11, 37] .
One must take into consideration that the peptides used in this and numerous other studies were synthetic, which limits the interpretation of biochemical and biophysical results in the context of AD development and progression. As shown by Meyer-Luehmann et al., brain-derived Aβ peptide mixtures differed considerably from synthetic mixtures in terms of their capacity to induce amyloid deposition in the rodent brain [17] . Nonetheless, our data provides further proof that the role N-terminally truncated, pyroglutamylated peptides have the potential to play a critical role in the development and progression of Alzhiemer's disease. Western blots confirm the presence of all peptides at the beginning of aggregation assays and that peptides were not degraded during aggregation. Western blots probed with antibody 4G8 show primarily monomeric peptides at the beginning of the assay; 4.5kDa Aβ1-42, 4.3kDa Aβp3-42, and 3. Electron micrographs of Aβ1-42 and Aβp3-42 peptides aggregated individually (6µM) and in mixtures for two and four hours. After incubation, 5µl of each sample was prepared for electron microscopy as described. Peptide mixture involving 4µM Aβ1-42 and 2µM Aβp3-42 consisted of bundles of aligned fibers after two hours of aggregation. (H) Images captured after four hours show the immature fibrillar structures with the flexions, curved fibers, and multistrand organization with occasional twisting similar to full-length Aβ1-42 alone. Magnification was 112,000; scale bars are 100µm.
